(Q26865514)

Madelene Lindqvist

series ordinal

2

1 reference

Ali M. Harandi

series ordinal

3

1 reference

language of work or name

1 reference

29 September 2015

1 reference

1 reference

33

1 reference

issue

40

1 reference

page(s)

5302-7

1 reference

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Genomic responses in mouse models poorly mimic human inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Genomic responses in mouse models greatly mimic human inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Alum adjuvant: some of the tricks of the oldest adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Key roles of adjuvants in modern vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

The mechanism of action of MF59 - an innately attractive adjuvant formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Molecular and cellular signatures of human vaccine adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Use of defined TLR ligands as adjuvants within human vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

TLR-based immune adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Toll-like receptors as adjuvant receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

CpG DNA as a vaccine adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Of mice and not men: differences between mouse and human immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Role of PD-1 in regulating acute infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Rational design of small molecules as vaccine adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Systems vaccinology: learning to compute the behavior of vaccine induced immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Current progress in computational metabolomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Innovation: Metabolomics: the apogee of the omics trilogy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Interactions between immunity and metabolism - contributions from the metabolic profiling of parasite-rodent models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

(1)H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Metabolomics of cerebrospinal fluid from humans treated for rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

DNA immunization perturbs lipid metabolites and increases risk of atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Vaccine adjuvants: a priority for vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Identifying gnostic predictors of the vaccine response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Towards systematic functional characterization of cancer genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Multiplex genome engineering using CRISPR/Cas systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.04.099

10.1016/J.VACCINE.2015.04.099

7 January 2021

Identifiers

DOI

0 references

PubMed publication ID

25989447

1 reference